ASTELLAS PHARMA KOREA, INC.
🇰🇷South Korea
A Study to Assess the Efficacy and Safety of Advagraf® Switching From Cyclosporine Between the Group That Was Treated With a 50% Reduced Corticosteroid and the Group With Maintained Corticosteroid for Stable Kidney Transplant Recipients
- First Posted Date
- 2014-01-13
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT02034747
A Study to Evaluate the Effect of Advagraf Conversion From Prograf in Liver Transplant Subjects
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT01882322
A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 138
- Registration Number
- NCT01839929
A Study to Evaluate the Effect of Tacrolimus and Corticosteroid Combination Therapy in Patients With Minimal Change Nephrotic Syndrome
Phase 4
Completed
- Conditions
- MCNSMinimal Change Nephrotic Syndrome (MCNS)
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT01763580
Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)
Phase 4
Completed
- Conditions
- Overactive BladderBenign Prostate HyperplasiaTransurethral Resection of ProstatePhotoselective Vaporization Prostatectomy
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-12-11
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT01747577
A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients
Phase 4
Completed
- Conditions
- Renal TransplantationKidney TransplantationStable Renal Recipients
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2014-08-05
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01742676
Study to Evaluate the Safety and Efficacy of Advagraf vs Prograf in Kidney Transplantation Patients 1 Month After the Transplantation
Phase 4
Completed
- Conditions
- de Novo Kidney Transplantation
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2014-10-10
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01742624
A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients
- First Posted Date
- 2011-03-16
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Korea, Inc.
- Target Recruit Count
- 37
- Registration Number
- NCT01316133
© Copyright 2025. All Rights Reserved by MedPath